Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
-
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
-
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class...
-
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class...